Francois J. Geoffroy

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma

William G. Breen, Jesse G. Dixon, S. Keith Anderson, Jann Nagina Sarkaria et autres

BACKGROUND: Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. METHODS: North Central Cancer Treatment Group N0877 is a phase 1 dose escalation and phase II randomized study evaluating the …

us (code pays fourni par la source)

Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).

Qian Shi, Tyler Zemla, Chao Ma, En Cheng et autres

LBA3509 Background: Systemic inflammation has been implicated in colon cancer progression. We examined whether intake of a proinflammatory diet is associated with survival among patients (pts) with stage III colon cancer. Methods: This prospective cohort study was nested within a randomized phase …

us, ca (code pays fourni par la source)

Development of brain metastases in non-small-cell lung cancer: high-risk features

Nolan Winslow, Jacqueline Anne Boyle, William Hallowes Miller, Yanzhi Wang et autres

Aim: Brain metastases (BM) are a common site of disease progression and treatment failure in non-small-cell lung cancer (NSCLC) and can be identified in up to 30–50% of patients. Although they are common, there is no standardized screening protocol for development of …

us (code pays fourni par la source)

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Linda M. Liau, Keyoumars Ashkan, Steven S. Brem, Jian Li Campian et autres

Importance: Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed. Objective: To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with …

us, gb, de, ca (code pays fourni par la source)

CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL

Linda M. Liau, Keyoumars Ashkan, Steven S. Brem, Jian Li Campian et autres

Abstract BACKGROUND Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years. We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and …

us, gb, de (code pays fourni par la source)

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Christopher Duma, Simon Khagi, Kevin O. Lillehei, Santosh Kesari et autres

Abstract Background Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma. Methods After surgery and chemoradiotherapy, patients were randomized …

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian Li Campian et autres

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original …

us, gb, de, ca (code pays fourni par la source)

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian Li Campian et autres

BACKGROUND: -L) to standard therapy for newly diagnosed glioblastoma. METHODS: After surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive DCVax-L, …

us, gb, de, ca (code pays fourni par la source)

Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance).

Nadia N. Laack, Evanthia Galanis, S. Keith Anderson, Clinton Leinweber et autres

2013 Background: Dasatinib is a potent oral ATP competitive multi-targeted kinase inhibitor of multiple members of the Src kinase family known to be involved in gliomagenesis, tumor invasion, and radiosensitivity. N0877 is a phase I/randomized phase II trial evaluating the combination of …

us (code pays fourni par la source)

Isolated CNS Hodgkin’s lymphoma: implications for tissue diagnosis

Derek L Martinez, Meena Gujrati, Francois J. Geoffroy, Andrew J. Tsung

CNS involvement in the setting of lymphoid neoplasia is a clinical situation that requires specific diagnosis due to the disparate treatment regimens recommended for neoplasms of specific lymphoid cell types. Cerebrospinal fluid (CSF) sampling may provide sufficient information to determine the presence …

us (code pays fourni par la source)

A randomized phase 2 study of temozolomide and bevacizumab or nab ‐paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma

Lisa A. Kottschade, Vera Jean Suman, Domingo G. Pérez, Robert R. McWilliams et autres

BACKGROUND: Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM). METHODS: A phase 2 trial was conducted in chemotherapy-naive patients with unresectable stage IV MM who were …

us (code pays fourni par la source)

Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study.

Nadia N. Laack, Evanthia Galanis, Clinton Leinweber, Jan C. Buckner et autres

2032 Background: Dasatinib is a potent oral ATP competitive multi-targeted kinase inhibitor of multiple members of the Src kinase family, known to be involved in gliomagenesis and invasion. N0877 is a phase I/randomized phase II trial evaluating the combination of dasatinib, radiation …

us (code pays fourni par la source)